Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

302 Followers
See the Price Targets and Ratings of:

RARE Analyst Ratings

Strong Buy
10Ratings
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RARE Stock 12 Months Forecast

Average Price Target

$88.30
▲(137.05% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $88.30 with a high forecast of $140.00 and a low forecast of $50.00. The average price target represents a 137.05% change from the last price of $37.25.
Highest Price Target$140.00Average Price Target$88.30Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Evercore ISI
$60.00
Hold
61.07%
Upside
Downgraded
Ultragenyx downgraded to In Line from Outperform at Evercore ISIUltragenyx downgraded to In Line from Outperform at Evercore ISI
Stifel Nicolaus
$135.00
Buy
262.42%
Upside
Reiterated
Ultragenyx Pharma (RARE) PT Lowered to $135 at StifelStifel analyst Dae Gon Ha lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $135.00 (from $142.00) while maintaining a Buy rating.
Piper Sandler
$130.00
Buy
248.99%
Upside
Reiterated
Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $130
Wedbush
$70.00
Hold
87.92%
Upside
Reiterated
Ultragenyx Pharma (RARE) PT Lowered to $70 at WedbushWedbush analyst Laura Chico lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $72.00) while maintaining a Neutral rating.
Bank of America Securities
$137.00
Buy
267.79%
Upside
Reiterated
Ultragenyx Pharma (RARE) PT Lowered to $137 at BofA SecuritiesBofA Securities analyst Tazeen Ahmad lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $137.00 (from $146.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

RARE Financial Forecast

RARE Earnings Forecast
Next quarter’s earnings estimate for RARE is -$2.10 with a range of -$3.33 to -$1.33. The previous quarter’s EPS was -$3.50. RARE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.35% of the time in the same period. In the last calendar year RARE has Underperformed its overall industry.
Next quarter’s earnings estimate for RARE is -$2.10 with a range of -$3.33 to -$1.33. The previous quarter’s EPS was -$3.50. RARE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.35% of the time in the same period. In the last calendar year RARE has Underperformed its overall industry.
RARE Sales Forecast
Next quarter’s sales forecast for RARE is $101.35M with a range of $95.30M to $110.40M. The previous quarter’s sales results were $90.70M. RARE beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 42.99% of the time in the same period. In the last calendar year RARE has Underperformed its overall industry.
Next quarter’s sales forecast for RARE is $101.35M with a range of $95.30M to $110.40M. The previous quarter’s sales results were $90.70M. RARE beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 42.99% of the time in the same period. In the last calendar year RARE has Underperformed its overall industry.
RARE Analyst Recommendation Trends
In the current month, RARE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RARE average analyst price target in the past 3 months is $88.30
In the current month, RARE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RARE average analyst price target in the past 3 months is $88.30

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is $88.30.
    What is RARE’s upside potential, based on the analysts’ average price target?
    Ultragenyx Pharmaceutical has 137.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RARE a Buy, Sell or Hold?
          Ultragenyx Pharmaceutical has a conensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Ultragenyx Pharmaceutical’s price target?
            The average price target for Ultragenyx Pharmaceutical is $88.30. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $140.00 ,the lowest forecast is $50.00. The average price target represents 137.05% Increase from the current price of $37.25.
              What do analysts say about Ultragenyx Pharmaceutical?
              Ultragenyx Pharmaceutical’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis